Epigral Ltd (formerly known as Meghmani Finechem Ltd), an integrated chemical manufacturer completed qualified institutional placement (QIP) by raised funds of ₹333.05 crore.
EPIGRAL raised funds will be deployed to support the company’s growth plans. The equity capital will further help Epigral to further strengthen its financial position while expanding its market presence.
Maulik Patel, Chairman and Managing Director, Epigral Ltd said, “We are thrilled to inform that we have received tremendous response from many marquee institutions, reflecting their confidence in our business and future growth potential. The proceeds from QIPs will be invested in the growth plans of the company. We are geared up to have volume growth based on the capex that we did in recent years and also we will be doing further capex to bring consistent growth and creating value for all our stakeholders”.
Epigral Limited (Epigral), formerly known as Meghmani Finechem Ltd, incorporated in 2007, is an integrated manufacturer of chemicals in India.
Epigral’s Dahej facility is a backward and forward integrated and automated complex with a
well-planned infrastructure. Epigral is the first in India to set up an epichlorohydrin plant and largest capacity plant of CPVC. Epigral also manufactures caustic soda, caustic potash, chloromethanes, hydrogen peroxide, chlorine and hydrogen.
The brand is strengthening its position in the specialty chemical segment by enhancing its capacity in CPVC, venturing into the Chlorotoluenes value chain and dedicated R&D centre. The company is focused on sustainable value creation for all its stakeholders and has been awarded with the Responsible Care certificate.
As per the press release, through integral collaborations and exceptional solutions, Epigral strives to enhance value and exceed expectations, leaving an indelible mark on stakeholders and the industry.
